API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MM-120 (lysergide D-tartrate) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at 5-HT2A receptors. It is being evaluated for the treatment of generalized anxiety disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of Attention-Deficit/Hyperactivity Disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of Attention-Deficit/Hyperactivity Disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of generalized anxiety disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Under the agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead candidate MM-120 (lysergide D-tartrate), which is currently in Phase 2 for generalized anxiety disorder.
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 03, 2023
Details:
MM-120 (lysergide D-tartrate) is a semi-synthetic hallucinogen or recreational drug, which is being investigated in patients with generalized anxiety disorder (GAD).
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
MM-120 (lysergide D-tartrate) is a semi-synthetic hallucinogen or recreational drug, which is being investigated in patients with generalized anxiety disorder (GAD)
Lead Product(s): Lysergide D-tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: MM-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023